AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Platelet-activating factor acetylhydrolase IB subunit alpha2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P68402

UPID:

PA1B2_HUMAN

Alternative names:

PAF acetylhydrolase 30 kDa subunit; PAF-AH subunit beta

Alternative UPACC:

P68402; A8DPS5; A8DPS6; A8DPS7; E9PEJ5; E9PLP3; O00687; Q29459; Q6IBR6

Background:

The Platelet-activating factor acetylhydrolase IB subunit alpha2, also known as PAF acetylhydrolase 30 kDa subunit or PAF-AH subunit beta, plays a pivotal role in modulating inflammatory responses. It achieves this by hydrolyzing the acetyl group at the sn-2 position of PAF and its analogs, thus regulating the action of PAF. This protein's activity and substrate specificity are influenced by its subunit composition, showcasing versatility in its function.

Therapeutic significance:

Understanding the role of Platelet-activating factor acetylhydrolase IB subunit alpha2 could open doors to potential therapeutic strategies. Its involvement in modulating inflammatory responses positions it as a key target for developing treatments aimed at inflammatory and possibly autoimmune diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.